These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15882529)

  • 21. Antibody profiling of canine IgG responses to the OspC protein of the Lyme disease spirochetes supports a multivalent approach in vaccine and diagnostic assay development.
    Oliver LD; Earnhart CG; Virginia-Rhodes D; Theisen M; Marconi RT
    Vet J; 2016 Dec; 218():27-33. PubMed ID: 27938705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conformational nature of the Borrelia burgdorferi decorin binding protein A epitopes that elicit protective antibodies.
    Ulbrandt ND; Cassatt DR; Patel NK; Roberts WC; Bachy CM; Fazenbaker CA; Hanson MS
    Infect Immun; 2001 Aug; 69(8):4799-807. PubMed ID: 11447153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a baited oral vaccine for use in reservoir-targeted strategies against Lyme disease.
    Bhattacharya D; Bensaci M; Luker KE; Luker G; Wisdom S; Telford SR; Hu LT
    Vaccine; 2011 Oct; 29(44):7818-25. PubMed ID: 21816190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of Surface Epitopes Associated with Protection against Highly Immune-Evasive VlsE-Expressing Lyme Disease Spirochetes.
    Batool M; Caoili SEC; Dangott LJ; Gerasimov E; Ionov Y; Piontkivska H; Zelikovsky A; Waghela SD; Rogovskyy AS
    Infect Immun; 2018 Aug; 86(8):. PubMed ID: 29866906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.
    Fawcett PT; Rose CD; Budd SM; Gibney KM
    Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A DNA vaccine encoding the outer surface protein C from Borrelia burgdorferi is able to induce protective immune responses.
    Scheiblhofer S; Weiss R; Dürnberger H; Mostböck S; Breitenbach M; Livey I; Thalhamer J
    Microbes Infect; 2003 Sep; 5(11):939-46. PubMed ID: 12941385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi.
    Golde WT; Piesman J; Dolan MC; Kramer M; Hauser P; Lobet Y; Capiau C; Desmons P; Voet P; Dearwester D; Frantz JC
    Infect Immun; 1997 Mar; 65(3):882-9. PubMed ID: 9038292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence for vaccine synergy between Borrelia burgdorferi decorin binding protein A and outer surface protein A in the mouse model of lyme borreliosis.
    Hanson MS; Patel NK; Cassatt DR; Ulbrandt ND
    Infect Immun; 2000 Nov; 68(11):6457-60. PubMed ID: 11035759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of an OspC-based tetravalent, recombinant, chimeric vaccinogen that elicits bactericidal antibody against diverse Lyme disease spirochete strains.
    Earnhart CG; Buckles EL; Marconi RT
    Vaccine; 2007 Jan; 25(3):466-80. PubMed ID: 16996663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection against tick-transmitted Lyme disease in dogs vaccinated with a multiantigenic vaccine.
    Straubinger RK; Dharma Rao T; Davidson E; Summers BA; Jacobson RH; Frey AB
    Vaccine; 2001 Oct; 20(1-2):181-93. PubMed ID: 11567763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eliminating Factor H-Binding Activity of
    Marcinkiewicz AL; Lieknina I; Kotelovica S; Yang X; Kraiczy P; Pal U; Lin YP; Tars K
    Front Immunol; 2018; 9():181. PubMed ID: 29472926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of the antigenic determinants of the OspC protein of the Lyme disease spirochetes: Evidence that the C10 motif is not immunodominant or required to elicit bactericidal antibody responses.
    Izac JR; Camire AC; Earnhart CG; Embers ME; Funk RA; Breitschwerdt EB; Marconi RT
    Vaccine; 2019 Apr; 37(17):2401-2407. PubMed ID: 30922701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Borrelia burgdorferi BBI39 Paralogs, Targets of Protective Immunity, Reduce Pathogen Persistence Either in Hosts or in the Vector.
    Singh P; Verma D; Backstedt BT; Kaur S; Kumar M; Smith AA; Sharma K; Yang X; Azevedo JF; Gomes-Solecki M; Buyuktanir O; Pal U
    J Infect Dis; 2017 Mar; 215(6):1000-1009. PubMed ID: 28453837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Live Attenuated Borrelia burgdorferi Targeted Mutants in an Infectious Strain Background Protect Mice from Challenge Infection.
    Hahn BL; Padmore LJ; Ristow LC; Curtis MW; Coburn J
    Clin Vaccine Immunol; 2016 Aug; 23(8):725-31. PubMed ID: 27335385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resolution of experimental and tick-borne Borrelia burgdorferi infection in mice by passive, but not active immunization using recombinant OspC.
    Zhong W; Gern L; Stehle T; Museteanu C; Kramer M; Wallich R; Simon MM
    Eur J Immunol; 1999 Mar; 29(3):946-57. PubMed ID: 10092099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A nonproliferating parvovirus vaccine vector elicits sustained, protective humoral immunity following a single intravenous or intranasal inoculation.
    Palmer GA; Brogdon JL; Constant SL; Tattersall P
    J Virol; 2004 Feb; 78(3):1101-8. PubMed ID: 14722265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DbpA, but not OspA, is expressed by Borrelia burgdorferi during spirochetemia and is a target for protective antibodies.
    Cassatt DR; Patel NK; Ulbrandt ND; Hanson MS
    Infect Immun; 1998 Nov; 66(11):5379-87. PubMed ID: 9784547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A study with a commercial vaccine against Lyme borreliosis in horses using two different vaccination schedules: Characterization of the humoral immune response.
    Knödlseder JM; Fell SF; Straubinger RK
    Vaccine; 2019 Nov; 37(49):7207-7212. PubMed ID: 31635975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters.
    Lovrich SD; Jobe DA; Schell RF; Callister SM
    Clin Diagn Lab Immunol; 2005 Jun; 12(6):746-51. PubMed ID: 15939749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial.
    Sikand VK; Halsey N; Krause PJ; Sood SK; Geller R; Van Hoecke C; Buscarino C; Parenti D;
    Pediatrics; 2001 Jul; 108(1):123-8. PubMed ID: 11433064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.